Intensity Therapeutics (INTS) Enterprise Value (2022 - 2026)

Intensity Therapeutics (INTS) has 5 years of Enterprise Value data on file, last reported at -$9.4 million in Q1 2026.

• Quarterly Enterprise Value fell 909.47% year-over-year to -$9.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$9.4 million (down 909.47% YoY) and the FY2025 annual result came in at -$11.9 million, down 451.39% from the prior year.
• Enterprise Value climbed to -$9.4 million in Q1 2026, from -$11.9 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of $10.0 million in Q4 2022 to a low of -$15.6 million in Q3 2023.
• A 5-year average of -$5.8 million and a median of -$6.5 million in 2024 frame the typical range for Enterprise Value.
• Annual changes were most pronounced in 2024 — Enterprise Value slumped 4238.38% — and 2025, when it soared 91.12%.
• Tracing INTS's Enterprise Value over 5 years: stood at $10.0 million in 2022, then plunged by 247.56% to -$14.8 million in 2023, then surged by 85.35% to -$2.2 million in 2024, then plunged by 451.39% to -$11.9 million in 2025, then rose by 21.33% to -$9.4 million in 2026.
• The last three Enterprise Value figures came in at -$9.4 million (Q1 2026), -$11.9 million (Q4 2025), and -$7.1 million (Q3 2025), per Business Quant data.